MOD-GRF (1-29) dosing reference
Common vial sizes, typical dose ranges, and a free reconstitution calculator pre-configured for MOD-GRF (1-29). Not medical advice. Always verify against your vial label and your provider's protocol.
MOD-GRF (1-29) reconstitution
Pre-loaded with common MOD-GRF (1-29) values — adjust to your vial.
Inputs
MOD-GRF (1-29) common vial sizes: 2 mg, 5 mg. Typical dose range: 0.1–0.2 mg. Research publications. Not medical advice.
for a 0.1 mg dose
- Concentration
- 1.00 mg/ml
- Volume
- 0.100 ml
- Per ml
- 100 u
Not medical advice. Always verify against your vial label and your provider's instructions. Re-check before drawing.
About MOD-GRF (1-29)
Growth-hormone-releasing peptides (GHRPs) and growth-hormone-releasing hormones (GHRH analogs) prompt the pituitary to release endogenous growth hormone. Common compounds include ipamorelin, CJC-1295 (with or without DAC), sermorelin, and tesamorelin.
How it's used
Subcutaneous injection, typically nightly or several nights per week, often before bed to align with the natural GH pulse. Many protocols stack a GHRP (e.g., ipamorelin) with a GHRH analog (e.g., CJC-1295) for synergy.
Storage
Refrigerate reconstituted vials at 36–46°F (2–8°C). GHRP-2/6, ipamorelin, and CJC variants are typically stable for 2–4 weeks reconstituted.
Watch for
- Tingling or numbness in extremities (especially with higher doses)
- Increased appetite (ghrelin-mimetic effect for GHRPs)
- Water retention or mild edema
- Fatigue or vivid dreams in the first week
Brand names & aliases
MOD-GRF (1-29) is also sold or referenced as ModGRF®, Mod-GRF®. These are registered trademarks of their respective owners and are listed for clinical clarity only — Peptide Calculator Log is not affiliated with, endorsed by, or sponsored by these companies.
MOD-GRF (1-29) vs other Growth Hormone peptides
5 compounds comparedReference dose ranges for the growth hormone category. Tap any compound to open its full reference page.
| Compound | Brand names | Typical dose | Vial sizes | Status |
|---|---|---|---|---|
| MOD-GRF (1-29) | ModGRF®, Mod-GRF® | 0.1–0.2 mg | 2, 5 mg | Research |
| Ipamorelin | — | 0.1–0.3 mg | 2, 5 mg | Research |
| CJC-1295 with DAC | CJC-1295 DAC® | 1–2 mg | 2, 5 mg | Research |
| CJC-1295 No DAC | Modified GRF 1-29® | 0.1–0.2 mg | 2, 5 mg | Research |
| CJC-1295 | CJC-1295 DAC®, CJC-1295 no DAC® | 0.1–0.3 mg | 2, 5 mg | Research |
Dose ranges summarized from FDA-approved labels (for approved compounds) and peer-reviewed research (for the rest). See the resources page for source databases.
MOD-GRF (1-29) FAQ
Answers, not hype.
MOD-GRF (1-29) (also marketed as ModGRF®, Mod-GRF®) is a peptide in the Growth Hormone category. It is a research peptide and is not FDA-approved for human use. The dose ranges shown (0.1–0.2 mg) are summarized from peer-reviewed research literature where evidence is preliminary.
MOD-GRF (1-29) most commonly ships in 2, 5 mg vials. Typical reconstitution volumes are 2, 3 ml of bacteriostatic water — choose the volume to land on a syringe-friendly unit count for your target dose.
Use the formula concentration = vial mg ÷ BAC water ml, then volume = dose mg ÷ concentration, then units = volume × 100 (for U-100). For example, a 2 mg vial reconstituted with 2 ml gives 1.00 mg/ml — at the typical low dose of 0.1 mg that resolves to 10.0 units. The free reconstitution calculator on this site verifies the math against your specific vial.
No. MOD-GRF (1-29) is a research peptide and is not FDA-approved for human use in the United States as of April 2026. Any use must come through a licensed healthcare provider, typically via a compounding pharmacy.
Side-effect profiles for research peptides are characterized in published research rather than an FDA label. Most users report mild local reactions at the injection site, occasional fatigue, and headache in the first few doses. Long-term human safety data is limited for most research compounds. Discuss with your prescribing provider before starting.
No. The values shown are reference numbers summarized from authoritative sources — FDA-approved labels for approved compounds and peer-reviewed research for the rest. They are not personalized recommendations. Always follow your prescribing provider's instructions and verify every calculation against your vial label.
References & sources
Research peptideMOD-GRF (1-29) is a research peptide. It is not FDA-approved for human use. The ranges shown above are summarized from peer-reviewed clinical and pre-clinical literature, where evidence remains preliminary. Discuss any use with a licensed healthcare provider.
- PubMed research literaturePeer-reviewed research on MOD-GRF (1-29). Evidence is preliminary; MOD-GRF (1-29) is not FDA-approved for human use.
- ClinicalTrials.govNIH database of registered clinical trials involving MOD-GRF (1-29), completed or in progress.
See the resources page for the full list of databases this site cross-checks against.
Track MOD-GRF (1-29) in the app
History, reminders, body-map injection rotation, Apple Watch logging, and a doctor-ready PDF — all bundled with the calculator.
Download on theApp Store